Abstract
Cancer immunotherapy is an increasingly common treatment option based on anti-tumor immune response. However, a challenge is arising regarding its potential, which is the poorly understood recognized immune-mediated adverse effects.
MeSH terms
-
Adenocarcinoma of Lung* / chemically induced
-
Adenocarcinoma of Lung* / drug therapy
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Gastritis* / chemically induced
-
Humans
-
Lung Neoplasms* / drug therapy
-
Lung Neoplasms* / pathology
Substances
-
Antibodies, Monoclonal, Humanized
-
pembrolizumab